This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

22 Biotech Stock Predictions for 2014

Twenty-two biotech predictions for 2014:

1. Vertex Pharmaceuticals (VRTX): The phase III studies of Kalydeco+VX-809 succeed, shares double.

2. Orexigen Therapeutics  (OREX): Contrave will outsell its obesity pill competitors Qsymia and Belviq. Likewise, Orexigen's stock will outperform Vivus (VVUS) and Arena Pharma  (ARNA).

3. Retrophin RTRX makes a hostile tender offer for Valeant Pharmaceuticals  (VRX).

4. Ongoing federal investigations of Questcor Pharmaceuticals  (QCOR) and its marketing practices for its flagship product Acthar Gel culminate in civil and criminal indictments against the company. CEO Don Bailey is forced to resign.

5. FDA rejects MannKind's  (MNKD) inhaled, rapid acting insulin Afrezza for the third time.

6. BioMarin Pharmaceuticals  (BMRN) will not be acquired. (Thereby guaranteeing BioMarin will be acquired.)

7. A Baker Brothers ETF is launched.

8. Tony Coles becomes CEO of Merck  (MRK).

9. Cellular therapy developer Neostem  (NBS) blows up on negative cardiac clinical trial data but CEO Robin Smith restructures company by opening a nationwide chain of stem-cell smoothie shops.

10. Amgen  (AMGN) will outperform the other big-cap biotech stocks, although all will finish the year higher than where they started.

11. Gilead Sciences  (GILD) will break out early on a strong launch of its hepatitis C pill Sovaldi but the stock finishes 2014 flattish -- a single-digit gain.

12. Weak, disappointing drug launches for Vanda Pharma  (VNDA) and Keryx Pharma  (KERX).

13. Avik Roy bashes Obamacare. (I have to make sure I get at least one of these damn predictions right.)

14. Twitter traders maintain their track record of never losing money on a biotech stock.

15. Peregrine Pharma (PPHM) manages to enroll 7 patients into its bavituximab phase III lung cancer trial, but that's five more than Cel-Sci  (CVM) manages to enroll in the Multikine head-and-neck cancer study.

16. Taken out in M&A deals: Regeneron Pharma  (REGN), Cempra  (CEMP), NPS Pharma  (NPSP), Clovis Oncology  (CLVS) and Halozyme  (HALO).

17. Raptor Pharma  (RPTP) proves not all orphan-drug launches are guaranteed successes as patients abandon Procysbi and insurance companies restrict reimbursement.

18. Dendreon  (DNDN)files for bankruptcy protection.

19. A coalition of private insurers and pharmacy benefits managers form a Super PAC to lobby Congress to consider implementation of European-style drug price controls.

20. Gene therapy developer Sangamo BioSciences  (SGMO) issues press release No. 689 claiming to cure HIV but still, no one believes them. Bluebird's  (BLUE) gene therapy program, however, proves to be the real deal.

21. Forbes' Matt Herper conducts another live interview with billionaire healthcare executive Patrick Soon-Shiong about his new healthcare tech venture NantWorks, but the audience still doesn't understand what the hell Soon-Shiong's company is supposed to be doing.

22. Cell Therapeutics' (CTIC) Jim Bianco wins Best Biotech CEO of 2014 (This is my black swan prediction.)

Here's a look back at how well my 2013 predictions fared:

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs